Notably, β1 overexpression was identified as an independent negative prognostic marker in ErbB2-positive breast cancer patients treated with trastuzumab, and β1-activated pathways such as PI3K/Akt or Erk circumvented the antiproliferative activity of trastuzumab in breast cancer cell lines [10]. This evidence concerns the gene AKT1 and breast carcinoma.